



The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee April 2024 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Adalimumab	Amgevita	Gastro-intestinal system	Approved	
2	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Approved	
3	Bempedoic acid	Nilemdo	Cardiovascular system	Rejected	Alternative(s) available in HADF with comparable benefits
4	Dostarlimab	Jemperli	Malignant disease and immunosuppression	Approved	
5	Fluticasone/Umeclidinium/Vilanterol	Trelegy Ellipta	Respiratory system	Pending	Pending further information
6	Glycerol phenylbutyrate	Ravicti	Nutrition and blood	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
7	Golimumab	Simponi	Musculoskeletal and joint disease	Pending	Pending further information
8	Insulin glargine	Toujeo	Endocrine system	Approved	
9	Lemborexant	Dayvigo	Central nervous system	Rejected	Insufficient evidence of long-term safety
10	Lenalidomide	Revlimid	Malignant disease and immunosuppression	Approved	
11	Lutetium 177 vipivotide tetraxetan	Pluvicto	Radiopharmaceuticals	Pending	Pending further information
12	Nivolumab	Opdivo	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits / The justification of the treatment's cost in relation to its benefits is insufficient
13	Nivolumab / Ipilimumab	Opdivo/ Yervoy	Malignant disease and immunosuppression	Approved	
14	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
15	Pembrolizumab / Axitinib	Keytruda/ Inlyta	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
16	Safinamide	Equfina	Central nervous system	Rejected	Insufficient comparative studies versus existing treatment
17	Trastuzumab Deruxtecan	Enhertu	Malignant disease and immunosuppression	Approved	

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
18	Upadacitinib	Rinvoq	Gastro-intestinal system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
19	Vedolizumab	Entyvio	Gastro-intestinal system	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.